Drugs that interfere with cannabinoid CB1 transmission suppress various food-motivated
behaviors, and it has been suggested that such drugs could be useful as appetite suppressants…

Background Activation of cannabinoid CB 1 receptors suppresses pathological pain but
also produces unwanted central side effects. We hypothesized that a positive allosteric …

Activation of cannabinoid CB 2 receptors suppresses neuropathic pain induced by traumatic
nerve injury. The present studies were conducted to evaluate the efficacy of cannabinoid …

The understanding of the pharmacology surrounding the cannabinergic system has seen
many advances since the discovery of the CB1 receptor in the mammalian brain and the CB2 …

The CB1 receptor is expressed in the central nervous system and numerous other tissues
including heart, lung and uterus and has been recognized as an important therapeutic target …

The cannabinoid 1 receptor (CB1R) is one of the most widely expressed metabotropic G
protein-coupled receptors in brain, and its participation in various (patho)physiological …

Multidrug resistance (MDR) significantly decreases the therapeutic efficiency of anti-cancer
drugs. Its reversal could serve as a potential method to restore the chemotherapeutic …

The α7 nicotinic acetylcholine receptor (nAChR) is a promising drug target for a number of
neurological disorders including chronic pain and inflammatory diseases. Since α7 can …

Spinal glial and proinflammatory cytokine actions are strongly implicated in pathological
pain. Spinal administration of the anti-inflammatory cytokine interleukin (IL)-10 abolishes …

The extensive physiological influence of transmission through the CB2 cannabinoid receptor
makes this G protein-coupled receptor (GPCR) a promising therapeutic target for treating …